Benralizumab (Fasenra) for Severe Eosinophilic Asthma: Targeting the IL-5 Receptor for Deeper Eosinophil Depletion

Reviewed by Frank Hull, MD — Pulmonologist, Advanced Asthma Clinic, Plantation, FL | Updated June 2026

Why Benralizumab Is Different: Receptor vs. Cytokine Targeting

Among the three approved anti-eosinophil biologics for severe asthma, benralizumab takes a fundamentally different approach. While mepolizumab and reslizumab bind the IL-5 cytokine itself — intercepting the signal before it reaches the cell — benralizumab binds directly to the alpha subunit of the IL-5 receptor (IL-5Rα) expressed on the surface of eosinophils and basophils.

This distinction matters clinically. By occupying the receptor rather than the ligand, benralizumab triggers an additional destruction mechanism unavailable to cytokine-targeting antibodies.

The ADCC Mechanism: How Benralizumab Kills Eosinophils

Benralizumab's Fc region is afucosylated — engineered to lack a specific sugar group that normally reduces binding affinity to immune effector cells. This modification dramatically increases the antibody's attraction to FcγRIII (CD16) receptors on natural killer (NK) cells and macrophages.

When benralizumab binds an eosinophil's IL-5Rα receptor, it simultaneously recruits NK cells via CD16 binding. The NK cell then releases cytotoxic granules directly onto the eosinophil, triggering apoptosis. This process — antibody-dependent cell-mediated cytotoxicity (ADCC) — produces near-complete eosinophil depletion in blood and tissue within days.

In clinical studies, benralizumab reduced blood eosinophil counts by approximately 90–99% — a deeper depletion than observed with IL-5 cytokine antagonists, which typically reduce counts by 50–70%. The clinical significance of this depth advantage is an active area of research, but it provides a mechanistic rationale for patients who have not responded adequately to other anti-eosinophil therapies.

Who Is a Candidate for Benralizumab?

The FDA label specifies severe eosinophilic asthma in patients 18 years and older who remain uncontrolled despite high-dose inhaled corticosteroids plus a long-acting beta-agonist. As an add-on maintenance therapy, benralizumab is not a rescue medication and does not replace existing controller regimens.

Eosinophil Thresholds and Response Prediction

Blood eosinophil count is the primary biomarker used to identify likely responders:

• ≥300 cells/μL: Strongest evidence for exacerbation reduction and lung function improvement — the population with the most consistent pivotal trial benefit
• 150–299 cells/μL: Meaningful benefit demonstrated in pooled analyses; clinical judgment required
• <150 cells/μL: Insufficient evidence for efficacy — benralizumab is not indicated in this group

A single eosinophil count is often sufficient to establish candidacy, but Dr. Hull typically reviews counts over 6–12 months to account for variability caused by oral corticosteroid use, which artificially suppresses eosinophils. Patients on chronic OCS may be better candidates than a single suppressed count suggests.

Distinguishing Features That Favor Benralizumab

Several patient profiles may favor benralizumab over other biologics:

• Dosing convenience: After three monthly loading doses, benralizumab transitions to Q8W (every-eight-week) maintenance — the least frequent dosing schedule of any approved asthma biologic. Mepolizumab requires monthly injections indefinitely; dupilumab requires every-other-week self-injection.
• OCS-dependent asthma: The ZONDA trial specifically enrolled OCS-dependent patients and demonstrated a 75% reduction in OCS dose with benralizumab vs. 25% with placebo.
• Prior anti-IL-5 partial responders: The receptor-targeting ADCC mechanism provides a mechanistically distinct option for patients who did not achieve adequate control on mepolizumab or reslizumab.
• No comorbid type 2 conditions driving choice: When IL-4/IL-13 pathway involvement (atopic dermatitis, nasal polyps) is absent and eosinophil count is the dominant biomarker, benralizumab's eosinophil specificity is well-matched to the clinical picture.

Clinical Trial Results: SIROCCO, CALIMA, ZONDA, and BORA

SIROCCO Trial

SIROCCO enrolled 1,204 patients with severe, uncontrolled eosinophilic asthma. In the eosinophil ≥300 cells/μL subgroup — the primary analysis population for the Q8W arm — benralizumab reduced annual exacerbation rate by 51% compared to placebo (rate ratio 0.49, 95% CI 0.37–0.64). Lung function improved by approximately 160 mL in FEV₁ from baseline.

CALIMA Trial

CALIMA confirmed SIROCCO findings in a complementary population on high-dose ICS/LABA. In the ≥300 cells/μL group, the Q8W arm achieved a 44% exacerbation rate reduction vs. placebo. FEV₁ improvement was approximately 116 mL. Patient-reported outcomes including Asthma Control Questionnaire (ACQ-6) and Asthma Quality of Life Questionnaire (AQLQ) showed statistically significant improvement.

ZONDA Trial: Oral Corticosteroid Reduction

ZONDA specifically targeted OCS-dependent severe asthma — patients requiring daily oral corticosteroids to maintain baseline control. At 28 weeks, the benralizumab group achieved a 75% median reduction in OCS dose, with 52% achieving complete OCS elimination, compared to 19% in the placebo group. This trial was instrumental in the approval's inclusion of OCS-sparing as a treatment goal.

For South Florida patients on chronic prednisone — carrying the cumulative risks of diabetes, osteoporosis, adrenal suppression, and weight gain — the OCS elimination potential is often the most compelling benefit discussed during consultation.

BORA Trial: Long-Term Safety and Q8W Durability

BORA was a 96-week open-label extension study that followed SIROCCO and CALIMA completers. Annual exacerbation rates remained low throughout the extension, and the safety profile was consistent with the placebo-controlled trials. No new safety signals emerged with prolonged use. The Q8W schedule was maintained without loss of efficacy, establishing long-term durability.

Dosing, Administration, and Self-Injection

The benralizumab dosing schedule is:

1. Month 1, 2, 3: 30 mg subcutaneous injection every 4 weeks (loading phase)
2. Month 5 onward: 30 mg subcutaneous injection every 8 weeks (maintenance)

The drug is available as a prefilled syringe or prefilled autoinjector. After training at Advanced Asthma Clinic, many patients elect to self-administer at home — a practical advantage for patients with demanding schedules. The subcutaneous injection is typically given in the upper arm, thigh, or abdomen.

Please consult your physician before making any decisions about medication administration. Self-injection is only appropriate after formal in-clinic training and medical clearance.

Safety Profile

Benralizumab has been studied in over 2,000 patients in controlled trials. The overall safety profile is favorable. The most common adverse events observed were:

• Injection site reactions: Pain, redness, and swelling at the injection site — generally mild and transient
• Pharyngitis: Upper respiratory tract symptoms, particularly in the first year
• Headache: Reported at rates similar to placebo in pooled analyses

Unlike dupilumab, benralizumab is not associated with conjunctivitis. Unlike systemic corticosteroids, it carries no metabolic, adrenal, or bone density risks. Hypersensitivity reactions (including anaphylaxis and angioedema) have been reported rarely; patients are monitored after the first injection.

Eosinophil Depletion and Infection Risk

Eosinophils play a role in defense against certain helminth (parasitic worm) infections. Patients with active or suspected parasitic infections should be treated before initiating benralizumab. This is clinically relevant in South Florida, where international travel is common and some parasitic exposures occur domestically.

Importantly, the deep eosinophil depletion from benralizumab has not been associated with increased bacterial or viral infection risk in clinical trials. The immune system relies primarily on neutrophils, T-cells, and antibodies for routine bacterial and viral defense.

Comparing Benralizumab to Other Asthma Biologics

Feature	Benralizumab (Fasenra)	Mepolizumab (Nucala)	Dupilumab (Dupixent)	Tezepelumab (Tezspire)
Target	IL-5Rα (receptor)	IL-5 (cytokine)	IL-4Rα (shared receptor)	TSLP
Mechanism add-on	ADCC eosinophil killing	Blocks IL-5 signaling	Blocks IL-4 and IL-13	Upstream alarm blockade
Eosinophil reduction	~90–99%	~50%	Variable (may increase early)	Moderate reduction
Eos threshold required	≥150 cells/μL	≥150 cells/μL	≥150 cells/μL or FeNO ≥25	None (phenotype-agnostic)
Dosing frequency	Q4W ×3 then Q8W	Q4W (ongoing)	Q2W (self-inject)	Q4W (self-inject after training)
OCS reduction trial	ZONDA (75% reduction)	SIRIUS (50% reduction)	VENTURE (70% reduction)	No dedicated OCS trial
Conjunctivitis risk	Not observed	Not observed	Significant (~10%)	Not observed
Covers non-eosinophilic	No	No	Partial (FeNO pathway)	Yes — all phenotypes

No single biologic is universally superior. The right choice depends on blood eosinophil count, comorbidities, IgE levels, FeNO, prior treatment history, injection frequency preference, and insurance coverage. Dr. Hull evaluates all these factors at consultation. Please consult your physician to determine which therapy is most appropriate for your individual situation.

What to Expect: Starting Benralizumab at Advanced Asthma Clinic

Pre-Treatment Evaluation

Before initiating benralizumab, Dr. Hull conducts a comprehensive evaluation that includes:

• Complete blood count with differential (blood eosinophil count and trend)
• Spirometry and lung function testing to establish baseline FEV₁
• FeNO measurement to characterize airway inflammation type
• Review of current OCS dose (if applicable)
• Assessment of comorbidities: nasal polyps, atopic dermatitis, GERD, obesity
• Allergy skin testing or serum IgE if not previously performed
• Evaluation for parasitic infection history or risk factors

First Injection and Observation

The first benralizumab injection is administered in the clinic. Patients are observed for at least 30 minutes for hypersensitivity reactions. Subsequent clinic visits at weeks 4 and 8 complete the loading phase; the third injection is sometimes given at home if the patient has been trained and is comfortable.

Monitoring on Therapy

After the loading phase, follow-up occurs every 8 weeks at the time of the maintenance injection. At each visit, Dr. Hull assesses:

• Symptom control (ACQ-6 score)
• Exacerbation frequency since last visit
• Rescue inhaler use
• Ability to reduce or eliminate OCS dose (for OCS-dependent patients)
• Side effects or tolerability concerns

Formal response assessment typically occurs at 4–6 months after initiating therapy. For most patients, meaningful improvements in symptoms and exacerbation frequency are evident within the first three months.

Benralizumab for OCS-Dependent Patients in South Florida

One of the most transformative applications of benralizumab in clinical practice is OCS reduction. A significant segment of severe asthma patients in Broward County and the greater Fort Lauderdale area arrive at Advanced Asthma Clinic on long-term prednisone — some for years — having accumulated substantial corticosteroid-related comorbidities.

The ZONDA trial protocol offers a structured approach: stabilize the patient on benralizumab during the loading phase, then begin a systematic OCS taper every 4 weeks, monitoring for exacerbations. In patients who achieve full OCS elimination, the benefits extend across multiple organ systems — improved glycemic control in diabetics, reduced blood pressure, recovery of adrenal function, reversal of weight gain, and improved bone density trajectory.

For patients on chronic OCS, this is not merely an asthma treatment — it is a comprehensive reduction in systemic disease burden. Please consult your physician to determine whether an OCS taper is appropriate and safe for your specific situation.

Insurance Coverage and Access

Benralizumab is covered by most major commercial insurance plans and Medicare Part B (administered as an in-office injection) or Part D (self-administered). Prior authorization is standard and requires documentation of:

• Diagnosis of severe asthma
• Current or prior high-dose ICS/LABA therapy
• Blood eosinophil count ≥150 cells/μL
• History of asthma exacerbations in the prior year

AstraZeneca's Fasenra One patient support program assists with prior authorization and provides co-pay support for commercially insured patients. For patients who remain uninsured or underinsured, clinical trials may provide access to investigational and approved biologics at no cost — contact our clinic to discuss options.

The Biologic Deep-Dive Series: Completing the Picture

Benralizumab completes the four-agent anti-eosinophilic biologic landscape for severe asthma. Advanced Asthma Clinic's comprehensive biologic series covers each agent's distinct mechanism:

• Mepolizumab (Nucala) — IL-5 cytokine blockade, the foundational anti-IL-5 agent
• Dupilumab (Dupixent) — IL-4/IL-13 dual blockade for type 2 inflammation with atopic comorbidities
• Tezepelumab (Tezspire) — Upstream TSLP blockade, the only biologic approved without an eosinophil threshold
• Benralizumab (Fasenra) — IL-5Rα receptor targeting with ADCC-enhanced eosinophil depletion (this article)

Understanding these mechanistic differences is the foundation of precision asthma care. At Advanced Asthma Clinic, Dr. Hull reviews each patient's biomarker profile — eosinophil count, FeNO, IgE, comorbidity pattern — and matches the mechanism to the individual. No single algorithm replaces clinical judgment, and the right biologic choice evolves as new data emerge.

Frequently Asked Questions

How quickly does benralizumab work?

Blood eosinophil counts drop dramatically within 24 hours of the first injection. Many patients report improvement in symptom burden within weeks. Meaningful exacerbation rate reduction is typically apparent after 3–6 months on therapy. Consult your physician for expectations specific to your case.

Can I stop benralizumab if I feel better?

Discontinuation is not recommended without physician guidance. While some patients maintain control for months after stopping, others experience gradual eosinophil return and exacerbation recurrence. This decision requires careful medical evaluation of your current lung function, eosinophil trends, and symptom history.

Can benralizumab be used with other biologics?

Combination biologic therapy is not currently an approved or standard approach. In cases of overlapping indications — for example, a patient with severe eosinophilic asthma and significant atopic dermatitis — the biologic with the broadest relevant coverage is typically selected. Consult your physician to evaluate options.

Is benralizumab safe during pregnancy?

Benralizumab has not been adequately studied in pregnant women. IgG antibodies cross the placenta during the second and third trimesters. Decisions about continuing or discontinuing biologic therapy during pregnancy must be made with your obstetrician and pulmonologist weighing the risks of uncontrolled severe asthma against theoretical fetal exposure.

Does benralizumab affect vaccines?

Patients on benralizumab should avoid live-attenuated vaccines. Inactivated vaccines — including influenza and pneumococcal vaccines — should be administered as recommended. Staying current on vaccinations is especially important for patients with severe asthma. Consult your physician regarding the timing of any vaccines.

Schedule a Biologic Consultation at Advanced Asthma Clinic

If you have severe eosinophilic asthma that is not controlled by inhaled medications, or if you are dependent on oral corticosteroids to manage your symptoms, a biologic evaluation may be the most important next step in your care.

Advanced Asthma Clinic serves patients throughout South Florida — Plantation, Fort Lauderdale, Davie, Weston, Coral Springs, Pembroke Pines, Hollywood, Deerfield Beach, and the greater Broward County region. Dr. Frank Hull brings over 20 years of pulmonary research experience and direct involvement in biologic clinical trials to every consultation.

Call us at 954-522-7226 to schedule your evaluation, or visit our contact page to request an appointment online. If cost is a concern, ask about the Better Breathing Grant program or clinical trial opportunities through our affiliated research site.

This content is provided for educational purposes only and does not constitute medical advice. Always consult your physician or qualified healthcare provider regarding diagnosis, treatment options, and any changes to your medication regimen. Benralizumab is a prescription medication approved by the FDA for specific indications; eligibility must be evaluated by a licensed physician.